Phase 12a Study to Assess Safety, Dosage, and Anti-Tumor Effects of PF-07248144 Alone and with Other Drugs in Advanced or Metastatic Solid Tumors

What this Trial Is About

Researchers are studying PF-07248144, a KAT6 inhibitor, to assess its safety, tolerability, how the body processes it pharmacokinetics, and its effects pharmacodynamics in people with advanced or metastatic solid tumors. The study also looks for early signs that PF-07248144 may work as a treatment, either alone or combined with other drugs. This is an open-label, multi-center trial with several parts for detailed evaluation. The study includes two main phases Part 1 focuses on dose escalation to find the best dose for PF-07248144 alone and in combination with other drugs like fulvestrant, palbociclib plus letrozole, PF-07220060 with fulvestrant, or vepdegestrant. Part 2 involves dose expansion to further assess PF-07248144 alone or in combination at the recommended doses from Part 1. Different combinations are tested in separate study arms to evaluate their safety and effects. Participants will undergo various assessments including monitoring for side effects and laboratory tests for up to 24 months. Researchers will measure drug levels in the blood, look for dose-limiting toxicities, and evaluate anti-tumor activity such as progression-free survival and overall survival. The study includes detailed safety monitoring and outcome measures to understand how PF-07248144 works and its impact on advanced or metastatic solid tumors.

Study of PF-07248144 in Advanced or Metastatic Solid Tumors